SPORE in Prostate Cancer

Publications

Found 55 results

Filters: First Letter Of Last Name is P [Clear All Filters]

2019

Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al.. 2019. Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3

Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al.. 2019. Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3

Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al.. 2019. Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3

Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X et al.. 2019. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.. J Clin Invest. 129(9):3924-3940.

Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X et al.. 2019. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.. J Clin Invest. 129(9):3924-3940.

Guo H, Ci X, Ahmed M, Hua JTony, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E et al.. 2019. ONECUT2 is a driver of neuroendocrine prostate cancer.. Nat Commun. 10(1):278.

Guo H, Ci X, Ahmed M, Hua JTony, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E et al.. 2019. ONECUT2 is a driver of neuroendocrine prostate cancer.. Nat Commun. 10(1):278.

Nowak DG, Katsenelson KCohen, Watrud KE, Chen M, Mathew G, D'Andrea VD, Lee MF, Swamynathan MMosur, Casanova-Salas I, Jibilian MC et al.. 2019. The PHLPP2 phosphatase is a druggable driver of prostate cancer progression.. J Cell Biol. 218(6):1943-1957.

Locallo A, Prandi D, Fedrizzi T, Demichelis F. 2019. TPES: tumor purity estimation from SNVs.. Bioinformatics. 35(21):4433-4435.

2020

Loda M, Bastos DC, Ribeiro CF, Ahearn T, Nascimento J, Pakula H, Clohessy J, Mucci L, Roberts T, Zanata SM et al.. 2020. Genetic ablation of FASN attenuates the invasive potential of prostate cancer driven by Pten loss.. J Pathol.

Liu D, Barbieri CE, Rubin MA, Demichelis F, Mosquera JMiguel, Elemento O, Sboner A, Shoag JE, Poliak D, Goueli RS et al.. 2020. Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes.. Nat Commun. 11(1):1987.

Liu D, Barbieri CE, Rubin MA, Demichelis F, Mosquera JMiguel, Elemento O, Sboner A, Shoag JE, Poliak D, Goueli RS et al.. 2020. Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes.. Nat Commun. 11(1):1987.

Butler LM, Perone Y, Dehairs J, Lupien LE, de Laat V, Loda M, Talebi A, Kinlaw WB, Swinnen JV. 2020. Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.. Adv Drug Deliv Rev. 159:245-293.

Stopsack KH, Huang Y, Tyekucheva S, Gerke TA, Bango C, Elfandy H, Bowden M, Penney KL, Roberts TM, Parmigiani G et al.. 2020. Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation.. Clin Cancer Res. 26(22):5903-5913.

Stopsack KH, Huang Y, Tyekucheva S, Gerke TA, Bango C, Elfandy H, Bowden M, Penney KL, Roberts TM, Parmigiani G et al.. 2020. Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation.. Clin Cancer Res. 26(22):5903-5913.

Park K, Rubin MA, Sboner A, Mosquera JMiguel, Elemento O, Tran H, Eng KW, Ramazanoglu S, Rolon RMMarrero, Scognamiglio T et al.. 2020. Performance Characteristics of a Targeted Sequencing Platform for Simultaneous Detection of Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, and Gene Fusions in Cancer Genome.. Arch Pathol Lab Med. 144(12):1535-1546.

Park K, Rubin MA, Sboner A, Mosquera JMiguel, Elemento O, Tran H, Eng KW, Ramazanoglu S, Rolon RMMarrero, Scognamiglio T et al.. 2020. Performance Characteristics of a Targeted Sequencing Platform for Simultaneous Detection of Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, and Gene Fusions in Cancer Genome.. Arch Pathol Lab Med. 144(12):1535-1546.

Rubin MA, Beltran H, Ballman KV, Sboner A, Cyrta J, Demichelis F, Augspach A, De Filippo MRosaria, Prandi D, Thienger P et al.. 2020. Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity.. Nat Commun. 11(1):5549.

Rubin MA, Beltran H, Ballman KV, Sboner A, Cyrta J, Demichelis F, Augspach A, De Filippo MRosaria, Prandi D, Thienger P et al.. 2020. Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity.. Nat Commun. 11(1):5549.

Rubin MA, Beltran H, Ballman KV, Sboner A, Cyrta J, Demichelis F, Augspach A, De Filippo MRosaria, Prandi D, Thienger P et al.. 2020. Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity.. Nat Commun. 11(1):5549.

Ricker E, Verma A, Marullo R, Gupta S, Ye C, Pannellini T, Manni M, Tam W, Inghirami G, Elemento O et al.. 2020. Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma.. Sci Rep. 10(1):13094.

Ricker E, Verma A, Marullo R, Gupta S, Ye C, Pannellini T, Manni M, Tam W, Inghirami G, Elemento O et al.. 2020. Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma.. Sci Rep. 10(1):13094.

Lehmann GL, Hanke-Gogokhia C, Hu Y, Bareja R, Salfati Z, Ginsberg M, Nolan DJ, Mendez-Huergo SP, Dalotto-Moreno T, Wojcinski A et al.. 2020. Single-cell profiling reveals an endothelium-mediated immunomodulatory pathway in the eye choroid.. J Exp Med. 217(6)

Conteduca V, Beltran H, Nanus DM, Tagawa ST, Mosquera JMiguel, Sboner A, Elemento O, Ku S-Y, Puca L, Slade M et al.. 2020. SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy.. Mol Cancer Ther. 19(5):1157-1164.

2021

Cotter KA, Gallon J, Uebersax N, Rubin P, Meyer KD, Piscuoglio S, Jaffrey SR, Rubin MA. 2021. Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-Low Induction of Therapy Resistance.. Mol Cancer Res. 19(8):1398-1411.